Study of a Pandemic Influenza Vaccine

Phase 1

Completed

• Conditions: Influenza

• Registration Number: NCT00136331
• Lead Sponsor: Seqirus

Brief Summary

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next avian influenza pandemic. This study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in healthy adults.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-08-26
• Study First Submitted QC: 2005-08-26
• Study First Posted: 2005-08-29
• Study Start: 2005-10
• Study Completion: 2006-11
• Status Verified: 2008-11
• Last Update Submitted: 2016-07-17
• Last Update Posted: 2016-07-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Healthy adults

Exclusion Criteria

• History of Guillain-Barre syndrome or active neurological disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Safety and immunogenicity

Trial Locations

Locations (2)

CMAX, a division of IDT Australia; 🇦🇺 Adelaide, South Australia, Australia

Murdoch Childrens Research Institute; 🇦🇺 Melbourne, Victoria, Australia